<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492437</url>
  </required_header>
  <id_info>
    <org_study_id>MS200095_0032</org_study_id>
    <secondary_id>2017-004074-34</secondary_id>
    <nct_id>NCT03492437</nct_id>
  </id_info>
  <brief_title>Effect of Tepotinib on the Pharmacokinetics (PK) of the P-glycoprotein (P-gp) Substrate Dabigatran Etexilate</brief_title>
  <official_title>Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-Glycoprotein by Investigating the Pharmacokinetics of the P-Glycoprotein Probe Substrate Dabigatran Etexilate in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of Tepotinib on the pharmacokinetics (PK) of the
      p-glycoprotein (P-gp) probe substrate Dabigatran etexilate.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 18, 2018</start_date>
  <completion_date type="Anticipated">July 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Time (t1/2) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/f) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/f) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) Obtained by Extrapolation (AUCextra%) of Dabigatran</measure>
    <time_frame>Pre-dose up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Assessments, 12-lead Electrocardiogram (ECG) Findings and Vital Signs</measure>
    <time_frame>Baseline up to Day 15</time_frame>
    <description>Number of participants with clinically significant changes will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate in treatment period 1 followed by tepotinib alone for 7 days and then tepotinib co-administered with Dabigatran in treatment period 2. Two treatment periods will be separated by a 3-day wash-out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate</intervention_name>
    <description>Participants will receive single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.</description>
    <arm_group_label>Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tepotinib</intervention_name>
    <description>Participants will receive single oral dose of Tepotinib for 8 days in Treatment period 2.</description>
    <arm_group_label>Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants of non-child bearing potential

          -  Body weight between 50 to 100 kilogram (kg)

          -  Body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m^2)

          -  A male participant must agree to use and to have his female partner of childbearing
             potential to use highly effective method of contraception

          -  Participant must have given written informed consent before any study-related
             activities

          -  All values for hematology, coagulation, and biochemistry tests of blood and urinalysis
             are within the normal range. Minor (solitary) non-clinically relevant deviation(s) are
             allowed as judged by the Investigator

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participation in a clinical study within 60 days prior to first drug administration

          -  Whole blood donation or loss of &gt; 450 milliliter (mL) within 60 days prior to first
             drug administration

          -  Any surgical or medical condition, or any other significant disease that could
             interfere with the study objectives, conduct, or evaluation

          -  Supine systolic blood pressure (SBP) greater than (&gt;) 140 millimeter of mercury (mmHg)
             or less than (&lt;) 90 mmHg, diastolic blood pressure (DBP) &gt; 90 mmHg or &lt; 50, and pulse
             rate &gt; 100 or less than or equals to (â‰¤) 40 beats per minute (bpm) at Screening and at
             admission on Day-1.

          -  12-Lead electrocardiograms (ECG) showing a corrected QT interval per Fridericia's
             formula (QTcF) &gt; 450 milliseconds (ms), PR &gt; 215 ms, or QRS &gt; 120 ms (at Screening)

          -  Creatinine clearance estimated glomerular filtration rate (eGFR) &lt; 90 milliliter per
             minute (mL/min) (at Screening)

          -  Participants with gall bladder removal or other relevant surgery of gastrointestinal
             tract

          -  History of any malignancy

          -  History of epilepsy

          -  Ascertained or presumptive allergy/hypersensitivity to the active drug substance
             and/or excipients

          -  Participants who in the Investigator's judgment were perceived as having an increased
             risk of bleeding

          -  Positive screen for alcohol or drugs of abuse (at Screening and Day -1)

          -  Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody
             (anti-HCV), and human immunodeficiency virus 1 and 2 antibodies (HIV1/HIV2 antibodies)
             (at Screening)

          -  Excessive consumption of xanthine-containing food or beverages before study drug
             administration until collection of last pharmacokinetic (PK) sample in each period (at
             Screening and Day -1)

          -  Receipt of any prescription or nonprescription medication within 14 days or 5
             half-lives, before study drug administration

          -  Smoker or former smoker who stopped smoking less than 6 months before the time of the
             Screening Visit

          -  Intake of grapefruit, Seville orange, cranberry or juices of these 3 fruits, or St.
             John's Wort, from 14 days prior to Day -1

          -  Inability to communicate or cooperate with the Investigator

          -  Other factors, which in the opinion of the Investigator may interfere with study
             conduct (at Screening and Day -1 of first Period only)

          -  Legal incapacity or limited legal capacity

          -  Participants kept in detention

          -  Abnormal liver function tests (alanine-amino-transferase [ALT] or
             aspartate-aminotransferase [AST] values above 1.1 x upper limit of normal [ULN]) at
             Screening. In case of marginal deviation, a re-testing is allowed for confirmation

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <zip>64293</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>P-glycoprotein</keyword>
  <keyword>Tepotinib</keyword>
  <keyword>Dabigatran Etexilate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Krestin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

